Silexion TherapeuticsSLXN
13F holders, Q3 2025 (September 30)4holders +2
3new positions
1sold out
$3.40avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Silexion Therapeutics Corp. (SLXN) in their 13F filings, up 2 from Q2 2025. 3 opened new positions and 1 sold out. The largest holders were Montag A & Associates Inc. ($10K), SBI Securities Co., Ltd. ($4K) and UBS Group AG ($2K).
- Company
- Silexion Therapeutics Corp.
- CUSIP
- G1281K130
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $14K |
| Exits | 1 | $16K |
All 13F filers, Q2 2025 → Q3 2025: 4,025 shares bought and 35,354 shares sold, net −31,329 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Montag A & Associates Inc. | 0.00% | New | 3,000 | $10K |
| SBI Securities Co., Ltd. | 0.00% | Reduce -93.5% | 1,060 | $4K |
| UBS Group AG | 0.00% | New | 692 | $2K |
| Pflug Koory, LLC | 0.00% | New | 333 | $1K |
"% of holder's portfolio" is SLXN's weight in each manager's 13F, not the share of Silexion Therapeutics Corp. the manager owns.